Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241084 | 0.81 | NPC1 (0.34) | TRPA1ESR1LMNATP53CYP1A2 | |
| SCHEMBL2532344 | 0.76 | GABRA1 (0.47) | DHFRTRPA1CA12CA1CA2 | |
| SCHEMBL3246174 | 0.74 | DHFR (0.42) | DHFRCA12CA1CA2CA9 | |
| SCHEMBL3240709 | 0.72 | PDE4B (0.37) | LMNACYP3A4MAPT | |
| SCHEMBL3742592 | 0.70 | GABRA1 (0.46) | CA1CA2GABRA1GABRB2LMNA | |
| SCHEMBL27843091 | 0.69 | LMNA (0.50) | DHFRTRPA1CA12CA1CA2 | |
| SCHEMBL10457926 | 0.68 | DHFR (0.44) | DHFRESR1CA12CA1CA2 | |
| SCHEMBL167078 | 0.67 | GABRA1 (0.55) | DHFRTRPA1CA12CA1CA2 | |
| SCHEMBL29414063 | 0.67 | GABRA1 (0.55) | DHFRTRPA1CA12CA1CA2 | |
| SCHEMBL6314140 | 0.67 | DHFR (0.45) | DHFRTRPA1ESR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1225163-B1 | Process for producing isopulegol | TAKASAGO PERFUMERY CO LTD (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-6774269-B2 | CYCLIZATION OF CITRONELLAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20020133046-A1 | Process for producing isopulegol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1225163-A2 | Process for producing isopulegol | Takasago International Corporation (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133046-A1 | Process for producing isopulegol | ACSL3, ACSL1, ACSL6 | DHFR 2623/4885TRPA1 1219/4885ESR1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.